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Abstract
Aims/hypothesis MicroRNAs (miRNAs) are short endoge-
nous RNAs that regulate multiple biological processes in-
cluding adipogenesis and fat metabolism. We sought to
identify miRNAs that correlate with BMI and to elucidate
their upstream regulation and downstream targets.
Methods Microarray-based expression profiling of 233
miRNAs was performed on subcutaneous abdominal adi-
pose tissue biopsies from 29 non-diabetic Pima Indian par-
ticipants. Correlation of the expression levels of eight
miRNAs with BMI was assessed by quantitative reverse
transcription (QRT) PCR in adipose samples from 80 non-
diabetic Pima Indians with a BMI of 21.6–54.0 kg/m2. The
upstream regulation of one of these miRNAs, miR-221, was
tested by treating cultured human pre-adipocytes with lep-
tin, TNF-α and insulin. Predicted targets of miR-221 were
validated using QRT-PCR, immunoblots and luciferase as-
says. The downstream effects of miR-221 overexpression
were assayed by proteomic analysis.
Results Expression levels of miR-221 were positively cor-
related with BMI (particularly in women) and fasting insulin
concentrations, while the levels of miR-193a-3p and miR-
193b-5p were negatively correlated with BMI; other
miRNAs did not show significant associations in the 80 sam-
ples. miR-221 was downregulated by leptin and TNF-α treat-
ment in cultured human pre-adipocytes. Conversely, miR-221
overexpression upregulated several proteins involved in fat
metabolism, mimicking peroxisome proliferator-activated re-
ceptor (PPAR) activation. Furthermore, miR-221 directly
downregulated the adiponectin receptor 1 (ADIPOR1) and
the transcription factor v-ets erythroblastosis virus E26
oncogene homolog 1 (ETS1). Adiponectin signalling is
known to promote insulin sensitivity, and ETS1 is crucial for
angiogenesis.
Conclusions/interpretation Our data suggest that miR-221
may contribute to the development of the insulin resistance
that typically accompanies obesity, by affecting PPAR sig-
nalling pathways and by directly downregulating ADIPOR1
and ETS1.
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Recent studies report the functional involvement of
microRNAs (miRNAs) in metabolic and endocrine path-
ways [1–3] and adipogenesis [4–8]. Differential expression
of miRNAs has been reported in the tissues of obese vs non-
obese human individuals [2, 6, 9, 10] and in humans and
animals with diabetes [11, 12]. However, the mechanisms of
action of most miRNAs that are deregulated in obesity are
unknown.
We used a hypothesis-free approach to identify miRNAs
in adipose tissue with expression levels that correlated with
BMI in Pima Indian individuals. We identified miR-221 as a
highly expressed candidate miRNA that was upregulated in
individuals with the highest BMIs, in agreement with pre-
vious studies [6, 13]. We then investigated the cause of miR-
221 upregulation in obesity and assessed possible molecular
mechanisms mediated by downstream targets of miR-221.
Methods
Participants and biopsy collection Participants were pre-
dominately of Pima Indian heritage and all were free of
diabetes. Biopsies and clinical data were available for 80
healthy individuals who were not taking any medication
(see electronic supplementary material [ESM] Table 1).
Participants were admitted to the Clinical Research Unit,
NIDDK, Phoenix, AZ, USA, where they consumed a
weight-maintaining diet (containing 50% of calories as car-
bohydrates, 30% as fat and 20% as protein) for 2–3 days
prior to clinical testing. A 3 h 75 g OGTT and abdominal
subcutaneous adipose tissue (SAT) needle biopsies under
local anaesthesia with 1% lidocaine were performed after a
12 h overnight fast. Variants in the miR-221 promoter were
analysed for association with BMI by genotyping in a
population-based sample of 3,500 Pima Indians (including
80 who underwent adipose tissue biopsies). Informed con-
sent was obtained for all participants, and the study was
approved by the institutional review board of the National
Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health (NIH).
RNA extraction, microRNA expression profiling and
validation Total RNA was extracted from 80 frozen SAT
biopsies using the miRNeasy kit (Qiagen, Venlo, the
Netherlands), quantified with a NanoDrop spectrophotome-
ter (Thermo Scientific, Wilmington, DE, USA), and its
integrity assayed on an Agilent 2100 BioAnalyzer (Agilent
Technologies, Santa Clara, CA, USA). Samples (n=29)
showing the highest quality RNA were labelled with the
3DNA FlashTag Biotin RNA Labeling kit (Genisphere,
Hatfield, PA, USA) and hybridised with GeneChip miRNA
arrays (Affymetrix, Santa Clara, CA, USA) for expression
profiling. Three random samples were rehybridised to new
arrays to ascertain reproducibility. The array cartridges were
processed on an Affymetrix Fluidics Station 450 and scanned
on an Affymetrix GeneChip 3000 7G with AutoLoader. The
results were normalised using the Affymetrix miRNAQC tool
and analysed with MeV software v4.3 [14] (Dana Farber
Cancer Institute, Boston, MA, USA) and Excel 2003
(Microsoft, Redmond, WA, USA).
Expression levels of specific miRNAs were validated in
all 80 RNA samples by quantitative reverse transcription
(QRT) PCR using TaqMan assays (Life Technologies,
Carlsbad, CA, USA) on an ABI 7900HT Fast QPCR system
(Life Technologies). U6 and U44 small nuclear RNAs were
used for normalisation. The differential expression of spe-
cific miRNAs was correlated to individuals’ BMI and insu-
lin and glucose levels during the OGTT. The homeostasis
model assessment 1 of insulin resistance (HOMA1-IR) was
calculated as previously described [15]. miRNA target
prediction used the TargetScan algorithm (for a list




Cell culture, treatment and transfection Primary human pre-
adipocytes (Zen-Bio, Research Triangle, NC, USA) and SH-
SY5Y human neuroblastoma-derived cells (American Type
Culture Collection (ATCC), Manassas, VA, USA) were
cultured in MEM/F-12 1:1 containing 10% FBS (ATCC).
Cells were serum-starved for 24 h and then treated with
recombinant human leptin (L4146; Sigma, St Louis, MO,
USA) at concentrations of 0, 50, 200 and 500 ng/ml, or
TNF-α (H8916; Sigma) at concentrations of 5–50 ng/ml, for
24 h prior to harvesting. Pre-adipocyte differentiation was
induced in DM-2 medium (Zen-Bio) for more than 10 days.
TNF-α treatment of differentiated adipocytes was for 10 or
16 days, at 10 or 100 ng/ml [18]. Insulin treatment was at
100 nmol/l for 1 h and 24 h. Total RNAwas extracted using
the miRNeasy kit (Qiagen).
For 3′ untranslated (UTR) reporter assays, JetPrime
(Polyplus-transfection SA, Illkirch, France) was used to co-
transfect HEK 293 cells (ATCC) with miRNA 3′ UTR target
expression vectors for human ETS1, ADIPOR1, ADIPOR2 or
control (Genecopoeia, Germantown, MD, USA), and human
miR-221 mimic (Dharmacon, Lafayette, CO, USA) or scram-
bled control oligonucleotide, in 24-well plates. Cells were
lysed 48 h post-transfection, and dual-luciferase readings were
performed using the Genecopoeia Luc-Pair miR Luciferase
Assay Kit on a TD-20/20 Luminometer (Turner Designs,
Sunnyvale, CA, USA). Transfection of pre-adipocytes for
immunoblotting and proteomic analysis was in six-well plates
and 75 cm2 flasks, respectively.
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Immunoblots We used Bio-Rad (Hercules, CA, USA) equip-
ment and reagents for immunoblots, and the following anti-
bodies: adiponectin receptor 1 (ADIPOR1; sc-99183; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and from Novus
Bio (Littleton, CO, USA), v-ets erythroblastosis virus E26
oncogene homolog1 (ETS1) (NBP1-47474), β-actin (NB600-
532), anti-mouse horseradish peroxidase (HRP;NB7539) and
anti-rabbit HRP (NB730-H).
Proteomic analysis Relative quantification of digested pep-
tides was performed by stable isotope labelling of primary
amines as previously described [19]. Dimethylated peptides
were separated by nanoflow liquid chromatography using a
Waters (Milford, MA, USA) nanoAcquity LC system. Data
dependent acquisition was used in the mass spectrometry
analysis on Thermo LTQ-Orbitrap Velos (Waltham, MA,
USA). Proteins were identified using Proteome Discoverer
1.3 (Thermo Scientific). Quantification was performed by
integrating the extracted ion chromatogram of the differen-
tially labelled peptides.
QRT-PCR for mRNAs This was performed on an ABI
7900HT Fast QPCR system using PerfeCTa FastMix
(Quanta BioSciences, Gaithersburg, MD, USA). Primer se-
quences are given in ESM Table 2. GAPDH expression was
used for normalisation.
Statistical analysis The statistical significance between
groups was determined using SigmaStat (SPSS, Chicago,
IL, USA) using two-way ANOVA, the Wilcoxon rank-sum
test for two independent samples, the Mann–Whitney U test
or the t test as appropriate.
Results
To identify miRNAs that might be relevant to studies of
obesity, miRNA array analyses were performed using the
GeneChip platform (Affymetrix) on RNA isolated from 29
abdominal SAT biopsies (ESM Fig. 1a). A comparison of
miRNA expression levels between individuals in the highest
tertile vs the lowest tertile of BMI (ten vs nine individuals,
respectively) identified several miRNAs that were differential-
ly expressed between the two groups (Fig. 1a). QRT-PCR was
used to validate both the mature and primary (pri)-miRNA for
these eight miRNAs in a larger sample of 80 individuals.
Three of the miRNAs, miR-221, miR-193a-3p and
miR193b-5p, were significantly correlated with BMI after
adjusting for age and sex (Fig. 1b–g, Table 1), at both the
mature and primary transcript levels; the other miRNAs
assayed in the larger sample did not show significant correla-
tionswith BMI that were consistent between themature and the
primary transcript forms. Sex differences were also analysed.
For thematuremiR-221, the correlation with BMIwas stronger
when the analysis was restricted to women (p<0.0001).
Although miR-221 maps to the X chromosome, there was no
significant difference in miR-221 expression between males
and females (data not shown). Expression levels for miR-193a-
3p, miR-193b-5p and miR-221 also showed nominal correla-
tions with plasma glucose levels or insulin responses to a 75 g
OGTT (Table 1). Since miR-221 displayed the highest expres-
sion levels in adipose tissue, we focused on this miRNA and
examined potential causes for its upregulation in obesity and
the effects of miR-221 on predicted downstream targets.
The upregulation of miR-221 in obesity could either be











































































































































Fig. 1 Profiling and validation of miRNAs associated with obesity in a
Pima Indian population. (a) miRNAs showing significantly different
(p<0.05, Wilcoxon rank-sum test for two independent samples) ex-
pression levels in adipose tissue from nine individuals with a BMI
below 30 kg/m2 (black bars; mean BMI 27.5 kg/m2; six men, three
women) vs 10 individuals with a BMI of 37.0 kg/m2 or more (white
bars; mean BMI 40.3 kg/m2; six men, four women). Error bars represent
SEM. (b–g) QRT-PCR validation of BMI-associated miRNAs, miR-221,
miR-193a-3p and miR-193b-5p, in 80 non-diabetic Pima Indians: (b–d)
primary transcripts; (e-g) mature miRNAs. A comprehensive list of
correlations and accompanying p values is given in Table 1
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secondary effect. To determine whether a variation in geno-
mic sequence was the primary cause, the promoter region of
miR-221 was sequenced using DNA from 24 unrelated Pima
Indian individuals. Two variants, rs2858060 and rs2745709,
were identified, and subsequent genotyping in a population-
based sample of Pima Indians (n=3,500) revealed no sig-
nificant association between either variant and BMI or miR-
221 expression levels in the 80 biopsies (data not shown).
This suggests that the positive correlation observed between
miR-221 expression and BMI is probably a consequence of
obesity.
It is well known that obesity is associated with higher
levels of leptin and TNF-α [20, 21], and also with a decrease
in insulin sensitivity accompanied by hyperinsulinaemia
[21]. Therefore, we examined whether leptin, TNF-α or
insulin could potentially affect the expression of miR-221.
Cultured human pre-adipocytes were treated with increasing
concentrations of leptin (50, 200 and 500 ng/ml) for 24 h.
Expression levels of miR-221 showed a dose-dependent
downregulation, the largest decrease occurring with
500 ng/ml of leptin (Fig. 2a). Leptin signalling affects the
brain as well as peripheral tissues; therefore, we tested
whether leptin could regulate miR-221 levels in a neuronal
cell model as well as in adipocytes. Treating SH-SY5Y
human neuroblastoma-derived cells with leptin (100 and
500 ng/ml) caused a trend of downregulation of miR-221
(Fig. 2b).
To assess the effects of TNF-α on miR-221 expression,
human pre-adipocytes were treated with 5, 10, 25 or
50 ng/ml of TNF-α for 24 h. Exposure to TNF-α for 24 h
resulted in a decrease in miR-221 expression levels at all the
concentrations tested (Fig. 2c). To evaluate the effects of
chronic exposure to TNF-α on miR-221 expression in
Table 1 Summary of associations between BMI, glucose and insulin responses to an OGTT (all traits adjusted for age and sex) and the expression
of mature and primary transcript (pri-) forms of miR-193a, miR-193b-5p and miR-221 in 80 SAT biopsies
miRNA type BMI 2 h glucose Fasting insulin 2 h insulin HOMA1-IR
(n=80) (n=80) (n=64) (n=64) (n=68)
miR-193a-3p R −0.004 −0.323
p 0.060 NS NS 0.009 NS
pri-miR-193a R −0.009 −0.440
p 0.010 NS 0.018 NS NS
miR-193b-5p R −0.006 −0.269 −0.267 −0.355 0.077
p 0.047 0.016 0.053 0.004 0.056
pri-miR-193b R −0.008 −0.273 −0.383 −0.37
p 0.015 0.014 0.014 0.0026 NS
miR-221 R 0.015 0.302 0.135
p <0.0001 NS 0.005 NS 0.066
miR-221
(women only, n=35)
R 0.644 0.736 0.506
p <0.0001 NS 0.042 NS 0.004
pri-miR-221 R 0.007
p 0.035 NS NS NS NS




















































































Fig. 2 miR-221 is downregulated by leptin and TNF-α in culture. (a)
QRT-PCR for miR-221 in primary human pre-adipocytes cultured with
or without 50–500 ng/ml leptin for 24 h. Error bars indicate SD (n=4).
*p=0.02 compared with non-treated (N/T) cells (two-tailed Mann–
Whitney U test). (b) QRT-PCR for miR-221 in the human neuronal
cell line SH-SY5Y cultured with or without 100 and 500 ng/ml leptin
for 24 h. Error bars indicate SD (n=3). (c) QRT-PCR for miR-221 in
primary human pre-adipocytes cultured with or without 5–50 ng/ml
TNF-α for 24 h. Error bars indicate SD (n=4). **p<0.01 compared
with N/T cells (two-tailed Mann–Whitney U test). (d) QRT-PCR for
miR-221 in differentiated human adipocytes cultured with or without
10 or 100 ng/ml TNF-α for 10 or 16 days. Error bars indicate SD (n=4).
**p<0.01 compared with N/T cells (two-tailed Mann–Whitney U test)
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differentiated adipocytes, human pre-adipocytes were treat-
ed with standard differentiation media and allowed to dif-
ferentiate for over 10 days. The adipocytes were then treated
with 10 or 100 ng/ml of TNF-α for 10 or 16 days. miR-221
expression levels were similarly decreased (Fig. 2d). In
contrast to leptin and TNF-α, no significant change in
miR-221 expression was observed following treatment with
100 nmol/l insulin (data not shown).
To find direct downstream targets of miR-221, the
TargetScan prediction program was used to identify genes
containing binding sites for the miRNA paralogs miR-221
and miR-222 (see Methods for the link containing the list of
predicted gene targets). Two of the predicted target genes,
ADIPOR1 (Fig. 3a) and ETS1 (Fig. 3b), could have a po-
tential role in causing insulin resistance as a consequence of
obesity and were therefore selected for further study.
To test whether miR-221 could downregulate ADOPOR1
and/or ETS1 expression, luciferase assays were performed
using ADOPOR1 and ETS1 3′ UTR reporter plasmids. To
assess binding in this artificial system, HEK 293 cells (selected
for rapid growth and ease of transfection) were co-transfected
with a miR-221 mimic or scrambled non-specific oligonucle-
otide (negative control) along with an ADIPOR1 3′ UTR
reporter plasmid, or with one of two ETS1 3′ UTR reporter
plasmids. The 3′ UTR of ETS1 is 3.6 kb in size and was
therefore cloned into two separate constructs with overlapping
sequence. A reporter plasmid containing the 3′ UTR of
ADIPOR2, which also functions as an adiponectin receptor
but has no predicted binding site for miR-221, was also tested.
The miR-221 mimic caused a significant reduction in lucifer-
ase activity for the ADIPOR1 and both ETS1 3′ UTR reporter
plasmids, but not for the ADIPOR2 3′ UTR plasmid
(Fig. 3c,d). In human pre-adipocytes, transfection with the
miR-221 mimic reduced the levels of endogenous ETS1
mRNA levels (Fig. 3e) but not ADIPOR1 mRNA (data not
shown). In contrast, both ETS1 andADIPOR1were reduced at
the protein level (Fig. 3f,g).
Since we had demonstrated that both leptin and TNF-α
could downregulate the expression of miRNA-221 and that
miRNA-221 could regulate ETS1 expression, we next de-
termined whether leptin and/or TNF-α treatment would
result in a downstream effect on ETS1 expression. Human
pre-adipocytes were treated with either leptin (50, 200 and
500 ng/ml) or TNF-α (10 ng/ml) for 24 h. ETS1 mRNA
expression levels were increased during treatment with both






















































































Position 3402-3408 of ETS1 3' UTR
5' ...UGAGGUAGCUUAGAGAUGUAGCG...
||| |||||||
3' CUUUGGGUCGUCUGU -UACAUCGA 5'
miR-221









Fig. 3 miR-221 targets the 3′ UTRs of ADIPOR1 and ETS1 and
decreases their protein levels. (a,b) TargetScan conserved predicted
miR-221 binding site on the 3′ UTRs of ADIPOR1 and ETS1. (c,d)
Quantification of dual-luciferase assay in HEK 293 cells co-transfected
with miR-221 mimic (black bars) or control oligonucleotide (white
bars) and ADIPOR1/2 (c) or ETS1 (d) 3′ UTR reporter plasmids. (d)
Two overlapping fragments of the ETS1 3′-UTR were subcloned into
separate vectors, indicated (A) and (B). Firefly/renilla luciferase ratio
(luc ratio) was normalised to no-UTR controls. Error bars indicate SD
(n=5). *p<0.05 (two-tailed Mann–Whitney U test). (e) Quantification
of QRT-PCR for ETS1 mRNA in human pre-adipocytes transfected
with miR-221 mimic (black bars) or control oligonucleotide (white
bars). Error bars indicate SD (n=3). (f) Immunoblots for ADIPOR1,
ETS1 and β-actin in human pre-adipocytes transfected with miR-221
mimic (+) or control oligonucleotide. (g) Quantification of the immu-
noblots shown in (f). Background-subtracted mean signal (n=2) for
ADIPOR1 and ETS1, normalised to the loading control (β-actin).
Black bars, miR-221 mimic; white bars, control oligonucleotide
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examine chronic exposure to TNF-α in adipocytes, differ-
entiated human adipocytes were treated with 10 and
100 ng/ml of TNF-α for 10 or 16 days. As with the pre-
adipocytes, ETS1 mRNA levels were increased in adipo-
cytes treated with TNF-α (Fig. 4c).
Specific analysis of ETS1 and ADIPOR1 as targets of
miR-221 was hypothesis-driven. To examine the effects of
miR-221 on protein expression with a hypothesis-free ap-
proach, mass spectrometry was used to perform a proteomic
analysis on human adipocytes transfected with miR-221.
Human pre-adipocytes were transfected with either a miR-
221 mimic or a scrambled non-specific siRNA control and
then treatedwith differentiationmedia for 10 days, before total
protein was harvested. Out of approximately 2,200 detectable
proteins, 251 (115 known and 136 uncharacterised) were
significantly (p<0.05) upregulated or downregulated in the
miR-221 mimic transfected cells compared with controls
(ESM Table 3). Only five of the 251 differentially regulated
proteins (upregulated: eukaryotic translation initiation factor 5
[EIF5]; member of the RAS oncogene family [RAB1A];
downregulated: guanine nucleotide binding protein alpha
inhibiting 2 [GNAI2]; thrombospondin 1 [THBS1]; tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation
protein, gamma polypeptide [YWHAG]) were predicted
miR-221 targets, suggesting that most observed changes in
protein levels were a downstream effect or that some miR-221
target genes were missed by the TargetScan prediction
program.
Ingenuity software was used to place the 115 known
differentially expressed proteins into physiological interac-
tion networks. The most significantly upregulated interac-
tion network (with a score of 43 and 20 focus molecules)
was that of energy production and fatty acid metabolism
(ESM Fig. 1b). This network included fatty acid synthase
(FASN), which was upregulated about fivefold in the miR-
221-transfected cells, and members of the aldoketoreductase
(AKR) family (AKR1C1–AKR1C4). The most significantly
downregulated network (with a score of 44 and 22 focus
molecules) was that of cellular assembly and maintenance
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Fig. 4 ETS1 is upregulated by leptin and TNF-α in culture. (a) QRT-
PCR for ETS1 mRNA in primary human pre-adipocytes cultured with
or without 50–500 ng/ml leptin for 24 h. Error bars indicate SD (n=4).
**p<0.01 (two-tailed Mann–Whitney U test). (b) QRT-PCR for ETS1
mRNA in primary human pre-adipocytes cultured with or without
10 ng/ml TNF-α for 24 h. Error bars indicate SD (n=3). *p<0.05
(two-tailed Mann–Whitney U test). (c) QRT-PCR for ETS1 mRNA in
differentiated human adipocytes cultured with or without 10 or 100 ng/
ml TNF-α for 10 or 16 days. Error bars indicate SD (n=3). **p<0.01
(two-tailed Mann–Whitney U test). (d) Quantification of QRT-PCR in
human pre-adipocytes transfected with miR-221 mimic (black bars) or
control oligonucleotide (white bars). HADHA/B, hydroxyacyl-CoA
dehydrogenase, α or β subunit, respectively. Error bars indicate SD
(n=3). *p<0.05 (two-tailed Mann–Whitney U test)
Table 2 Top common regulators predicted to effect the proteomic changes observed in cultured adipocytes overexpressing miR-221, using
Ingenuity pathway analysis software
Regulator Molecule type Predicted state z score p values of overlap
MYCN Transcription regulator 1.913 1.05×10−10
INSR Kinase 1.782 6.24×10−10
Pirinixic acid Chemical toxicant Activated 3.268 2.57×10−9
Bezafibrate Chemical drug Activated 2.184 1.19×10−8
TP53 Transcription regulator 0.692 4.05×10−8
PPARα Ligand-dependent nuclear receptor Activated 3.108 6.44×10−8
Dinoprost Chemical – endogenous 0.254 7.10×10−8
PPARγ Ligand-dependent nuclear receptor Activated 2.601 1.62×10−7
Mannose Chemical – endogenous 1.000 2.52×10−7
ACOX1 Enzyme 0.113 4.57×10−7
MYCN, v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian); INSR, insulin receptor; ACOX1, acyl-coenzyme A
oxidase 1, palmitoyl
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To determine whether proteins upregulated by miR-221 in
the proteomic analysis were also upregulated at the mRNA
level, QRT-PCR was used to measure the mRNA levels of
seven of them (AKR1C1–AKR1C4, FASN, HADHA and
HADHB) following miR-221 overexpression. Among these
targets, AKR1C4 and HADHAwere significantly upregulated
by miR-221, while several others showed a non-significant
trend (Fig. 4d). Other affected proteins may be regulated post-
transcriptionally by downstream effectors of miR-221.
Prediction of upstream regulators that could potentially
control several of the differentially expressed proteins
yielded four molecules with high activation scores
(Table 2). Two of these predicted common regulators (perox-
isome proliferator-activated receptor (PPAR)α and PPARγ)
belong to the PPAR family, while the other two (pirinixic acid
and bezafibrate) are PPAR agonists. Therefore, overexpression
of miR-221 in cultured adipocytes appears to affect the prote-
ome in a manner that mimics PPAR activation.
Discussion
Our results show that adipose miR-221 expression is posi-
tively correlated with increasing BMI in the Pima Indian
population. This correlation is in agreement with previous
reports also showing that adipose miR-221 is upregulated in
obesity [6, 13]; however, the mechanism(s) for the
upregulation in our study are unclear. Both leptin and
TNF-α, whose levels are known to be increased in the obese
state, were found to downregulate miR-221 in cultured cells.
This suggests a more complex mechanism in vivo, which
may include desensitisation to the effects of leptin and
TNF-α in the chronically obese state [22–25].
In our proteomic analysis, we sought to identify the
downstream consequences of miR-221 upregulation. The
most significantly upregulated physiological network in ad-
ipocytes transfected with miR-221 consists of proteins in-
volved in fatty acid metabolism, including FASN. It is
thought that increased levels of fatty acids and increased
expression of FASN may play a role in the development of
insulin resistance [26–29]. Prediction of upstream regulators
that can activate several of the differentially expressed pro-
teins yielded PPARα, PPARγ and two PPAR agonists,
which may again indicate that upregulation of miR-221 in
the obese state activates pathways involved in insulin
sensitivity [30, 31].
We have further shown that miR-221 directly downregulates
ADIPOR1 and ETS1 expression; therefore, it may be possible
that obesity-associated upregulation of miR-221 can result in a
decrease in ADIPOR1 and/or ETS1, which may in turn lead to
the development of obesity-related metabolic consequences
such as insulin resistance or type 2 diabetes. ADIPOR1 func-
tions as a receptor for adiponectin and mediates a signalling
pathway that promotes insulin sensitivity and is suppressed in
insulin resistance and type 2 diabetes caused by obesity [32].
ETS1 is a transcription factor that regulates the expression of a
wide spectrum of genes including cytokines and chemokines
[33], and it has been proposed that obesity-associated inflam-
mation may also play a significant role in the development of
type 2 diabetes [34].
In addition, the previously described role of ETS1 in
vascular endothelial growth factor (VEGF)-induced angio-
genesis through its regulation of matrix metalloproteinases
(MMPs) [35] that is subject to regulation by other miRNAs,
e.g. miR-199a-5p [36], and the importance of VEGF signal-
ling for adipose function [37] suggest that higher miR-221
expression in obesity may lead to decreased vascularisation
and increased hypoxia and inflammation in adipose tissue.
Supporting this notion is our group’s previous report that
MMP3, a target of ETS1 [38], is downregulated in pre-
adipocytes and stromal vascular cells from obese individuals
[39], and that genetic variation in the MMP3 locus is only
partially responsible for this downregulation. Additionally,
downregulation of ETS1 may be essential to PPAR signal-
ling [40], in line with the observed proteomic effects in
which miR-221 overexpression mimicked PPAR activation.
ETS1 and ADIPOR1 were absent from the list of proteins
detected in our mass spectrometry analysis, possibly due to
an overall lower expression level of these proteins, as well
as a bias against membrane (such as ADIPOR1) and nuclear
(such as ETS1) proteins inherent in the purification method
employed.
miR-221 is a known player in oncogenesis, affecting the
proliferation and behaviour of various cell types [41–47].
Deregulation of ETS1 in a variety of cancers suggests that
ETS1 could mediate the effects of miR-221 in oncogenesis.
Recent studies have shown that an ETS1-mediated transcription
of members of the MMP family is responsible for remodelling
of the extracellular matrix in both angiogenesis and invasion
[48]. Resistance to TNF-α promotes tumourigenesis [49, 50],
and elevated miR-221 may have a role in mediating these
effects via its suppression of ETS1 [51]. Thus, chronic
upregulation of miR-221 in obesity may potentially increase
cancer risk. However, additional studies are required to dem-
onstrate that miR-221 is a valid link between obesity and
obesity-associated diseases such as the metabolic syndrome,
type 2 diabetes and cancers.
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